Malathion

CHEMBL1200468 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
330.4 g/mol
LogP
2.4
Phase
4

An organophosphate compound used medically as a topical treatment for head lice infestations, working by inhibiting acetylcholinesterase in the lice's nervous system to kill both adult lice and their eggs. It is applied directly to dry hair, left for a set period, and then washed out, usually requiring a repeat application after about a week.

Moleküler Ağırlık

330,4000 g/mol

LogP

2,40

TPSA

128,00 Ų

Lipinski RO5

Geçer

Etki Mekanizması

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC

InChI

InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3

Molecular Formula

C10H19O6PS2

HBD / HBA

- / 8

Döndürülebilir Bağlar

11

Ağır Atomlar

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An organophosphate compound used medically as a topical treatment for head lice infestations, working by inhibiting acetylcholinesterase in the lice's nervous system to kill both adult lice and their eggs. It is applied directly to dry hair, left for a set period, and then washed out, usually requiring a repeat application after about a week.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Malathion is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200468. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 4004. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.